Spots Global Cancer Trial Database for An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness
Study ID: NCT03669588
Conditions
Study Description
Brief Summary: A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Investigator Site 29, Phoenix, Arizona, United States
Investigator Site 66, Carlsbad, California, United States
Investigator Site 5, Los Angeles, California, United States
Investigator Site 49, Los Angeles, California, United States
Investigator Site 18, Orange, California, United States
Investigator Site 40, Palo Alto, California, United States
Investigator Site 59, San Francisco, California, United States
Investigator Site 58, Aurora, Colorado, United States
Investigator Site 34, Jacksonville, Florida, United States
Investigator Site 4, Tampa, Florida, United States
Investigator Site 30, Springfield, Illinois, United States
Investigator Site 25, Iowa City, Iowa, United States
Investigator Site 21, Kansas City, Kansas, United States
Investigator Site 27, Boston, Massachusetts, United States
Investigator Site 48, Detroit, Michigan, United States
Investigator Site 53, Buffalo, New York, United States
Investigator Site 3, Chapel Hill, North Carolina, United States
Investigator Site 20, Cleveland, Ohio, United States
Investigator Site 9, Portland, Oregon, United States
Investigator Site 17, Charleston, South Carolina, United States
Investigator Site, Cordova, Tennessee, United States
Investigator Site 44, Houston, Texas, United States
Investigator Site 6, San Antonio, Texas, United States
Investigator Site 2, Charlottesville, Virginia, United States
Investigator Site 16, Seattle, Washington, United States
Investigator Site 11, Edegem, , Belgium
Investigator Site 8, Ghent, , Belgium
Investigator Site 38, Edmonton, Alberta, Canada
Investigator Site 24, Toronto, Ontario, Canada
Investigator Site 22, Montréal, Quebec, Canada
Investigator Site 32, Brno, , Czechia
Investigator Site 35, Ostrava-Poruba, , Czechia
Investigator Site 51, Praha 2, , Czechia
Investigator Site 36, Aarhus, , Denmark
Investigator Site 15, Copenhagen, , Denmark
Investigator Site 13, Bordeaux Cedex, , France
Investigator Site 52, Marseille, , France
Investigator Site 46, Tbilisi, , Georgia
Investigator Site 45, Tbilisi, , Georgia
Investigator Site 47, Tbilisi, , Georgia
Investigator Site 33, Berlin, , Germany
Investigator Site 55, Budapest, , Hungary
Investigator Site 54, Szeged, , Hungary
Investigator Site 10, Milano, , Italy
Investigator Site 12, Napoli, , Italy
Investigator Site 42, Chiba-shi, Chiba, Japan
Investigator Site 26, Sapporo, Hokkaido, Japan
Investigator Site 19, Hanamaki, Iwate, Japan
Investigator Site 43, Sendai, Miyagi, Japan
Investigator Site 50, Suita, Osaka, Japan
Investigator Site 28, Ōsaka-sayama, Osaka, Japan
Investigator Site 31, Meguro, Tokyo, Japan
Investigator Site 41, Minato-Ku, Tokyo, Japan
Investigator Site 39, Shinjuku-Ku, Tokyo, Japan
Investigator Site 37, Leiden, , Netherlands
Investigator Site 7, Gdańsk, , Poland
Investigator Site 57, Katowice, , Poland
Investigator Site 14, Kraków, , Poland
Investigator Site 23, Warszawa, , Poland
Investigator Site 64, Krasnoyarsk, , Russian Federation
Investigator Site 62, Nizhny Novgorod, , Russian Federation
Investigator Site 65, Novosibirsk, , Russian Federation
Investigator Site 60, Samara, , Russian Federation
Investigator Site 61, Belgrade, , Serbia
Investigator Site 63, Edgbaston, , United Kingdom
Investigator Site 56, Liverpool, , United Kingdom
Contact Details
Name: Antonio Guglietta, MD
Affiliation: argenx
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
